Euthymics Bioscience, Inc. Closes $24 Million Series A Financing and Completes Acquisition of DOV Pharmaceutical
Posted by admin | Filed under Oxycontin Addictions
More info…
CAMBRIDGE, Mass.—-Euthymics Bioscience, Inc., a clinical-stage company developing next-generation antidepressants, today announced the completion of a Series A financing — led by Novartis Venture Funds and Venture Investors for a total investment commitment of $24 million in milestone-conditioned tranches.
Tags: oxycontin addiction
Leave a Reply
You must be logged in to post a comment.